Cell Signaling Technology

Product Pathways - Tyrosine Kinase / Adaptors

HER3/ErbB3 (1B2E) Rabbit mAb #4754

Applications Reactivity Sensitivity MW (kDa) Isotype
W IP H (M) (R) Endogenous 185 Rabbit IgG

Applications Key:  W=Western Blotting  IP=Immunoprecipitation
Reactivity Key:  H=Human  M=Mouse  R=Rat
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

HER3/ErbB3 (1B2) Rabbit mAb detects endogenous levels of total HER3/ErbB3 proteins. This antibody does not cross-react with other ErbB family members.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Tyr867 of human ErbB3.

Western Blotting

Western Blotting

Western blot analysis of MCF7 and T47D cell lysates, using HER3/ErbB3 (1B2) Rabbit mAb.

Background

HER3/ErbB3 is a member of the ErbB receptor protein tyrosine kinase family, but lacks tyrosine kinase activity. Tyrosine phosphorylation of ErbB3 depends on its association with other ErbB tyrosine kinases. Upon ligand binding, heterodimers form between ErbB3 and other ErbB proteins and ErbB3 is phosphorylated on tyrosine residues by the activated ErbB kinase (1,2). There are at least 9 potential tyrosine phosphorylation sites in the carboxy-terminal tail of ErbB3. These sites serve as consensus binding sites for signal transducing proteins, including Src family members, Grb2, and the p85 subunit of PI3 kinase, which mediate ErbB downstream signaling (3). Both Tyr1222 and Tyr1289 of ErbB3 reside within a YXXM motif and participate in signaling to PI3 kinase (4).ErbB3 is highly expressed in many cancer cells (5) and activation of the ErbB3/PI3K pathway is correlated with malignant phenotypes of adenocarcinomas (6). In tumor development, ErbB3 may function as an oncogenic unit together with other ErbB members (e.g. ErbB2 requires ErbB3 to drive breast tumor cell proliferation) (7). Thus, inhibiting interaction between ErbB3 and ErbB tyrosine kinases has become a novel strategy for anti-tumor therapy.

  1. Yarden, Y. and Sliwkowski, M.X. (2001) Nature Rev. Mol. Cell. Biol. 2, 127-137.
  2. Guy, P.M. et al. (1994) Proc. Natl. Acad. Sci. USA 91, 8132-8136.
  3. Songyang, Z. et al. (1993) Cell 72, 767-778.
  4. Kim, H.H. et al. (1994) J. Biol. Chem. 269, 24747-24755.
  5. Sithanandam, G. et al. (2003) Carcinogenesis 24, 1581-1592.
  6. Kobayashi, M. et al. (2003) Oncogene 22, 1294-1301.
  7. Holbro, T. et al. (2003) Proc. Natl. Acad. Sci. USA 100, 8933-8938.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

Rabbit Monoclonals Produced Using Epitomics® Technology, U.S. Patent No. 5,675,063.

This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.

Products